Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) edged up 0.20% to HKD 14.780 in early trading
Newtimespace News, as of 10:45 on May 12, Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) was quoted at HKD 14.780, up 0.20%. The ETF opened at HKD 14.750, with an intraday high of HKD 14.850 and a low of HKD 14.700. The latest NAV per unit is HKD 14.780, with a discount rate of 0.20% (i.e., a premium of -0.20%). The asset size is approximately HKD 2.294 billion.
Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) tracks the Hang Seng Biotech Index, which is compiled and published by Hang Seng Indexes Company Limited. The index aims to track the overall performance of the 30 largest biotech companies by market capitalization that are listed in Hong Kong and eligible for Southbound Stock Connect trading. Its constituent holdings cover four major business sub-categories: pharmaceuticals, biotechnology, pharmaceutical distribution, and medical equipment & supplies, focusing on core biotech fields such as innovative drugs, CXO, and medical devices. The index provides investors with a high-purity tool for concentrated investment in Hong Kong-listed leading biotech companies and capturing the development trends of pharmaceutical innovation.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Biotech Index Hits a Year-to-Date High as Innovative Drug and CXO Names Rally; CSOP Hang Seng Biotech ETF (3174.HK) Gains 3.18% and Is Up 17.93% Year-to-Date
- Korean Stocks Open Higher but Close Lower as Semiconductor Heavyweights Slip; Csop Kospi 200 Etf (03121.HK) Falls 1.30%
- KINETIC DEV (01277.HK): Sierra Leone Rutile Project Commences Production
- CNE TECH CORP (00611.HK): Acquisition Consideration Adjusted Down to RMB71.93m
- BEONE MEDICINES (06160.HK): Grants RSUs Over 52,482 ADSs to 277 Grantees